Biden and Becerra Slated to Speak at NACHC Event Next Week

President Joe Biden (left) and HHS Secretary Xavier Becerra are scheduled to speak on Monday, Feb. 14, during the National Association of Community Health Centers’ (NACHC) Policy and Issues Virtual Forum.

President Joe Biden and U.S. Health and Human Services (HHS) Secretary Xavier Becerra are scheduled to speak on Monday, Feb. 14, during the National Association of Community Health Centers’ Policy and Issues Virtual Forum, NACHC announced on Tuesday.

Securing Biden

Read More »

HRSA Says at Least Three Hospitals Have Lost 340B Eligibility So Far Due to COVID-19 Patient Mix Changes

St. Elizabeth Healthcare in Ft. Thomas, Ky., is one of three hospitals known to have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. More are expected to lose eligibility soon.

The U.S. Health Resources and Services Administration (HRSA) said yesterday it knows of three hospitals that have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. There could

Read More »

News Alert: At 340B Conference, Feds Laud 340B Providers, Criticize Drug Makers Embroiled in Contract Pharmacy Fight

U.S Assistant Surgeon General Krista Pedley (left) and OPA Acting Director Michelle Herzog told health care providers attending the 340B Coalition winter conference they back them in the 340B contract pharmacy fight.

340B program federal administrators told health care providers attending the 340B Coalition winter conference in San Diego today that they are behind them in the battle with drug manufacturers over accessing 340B pricing in the contract pharmacy setting.

The U.S.

Read More »

Exclusive: Nearly Five Years Before BMS Voluntarily Opened Up Myeloma Drug Network, HRSA Told Celgene it “Must Ensure” Entities Could Buy at 340B Price

Bristol Myers Squibb said Jan. 14 it voluntarily will let 340B covered entities buy Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through specialty pharmacies in the company's limited distribution network for the drugs. BMS acquired the drugs in 2019 when it acquired Celgene. In 2017, HRSA told Celgene it had to ensure that 340B entities could buy the drugs at 340B price through the same limited distribution network.

The U.S. Health Resources and Services Administration (HRSA) told drug manufacturer Celgene nearly five years ago the company “must ensure” that covered entities could buy its cancer drugs Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through Celgene’s limited

Read More »

Health Center Opposes AstraZeneca’s Motion to Pause 340B Dispute Resolution Proceedings Over Company’s Contract Pharmacy Policy

A Vermont health center asked a 340B dispute resolution panel to reject AstraZeneca's motion to stay the proceedings.

A Vermont community health center that co-initiated 340B administrative dispute resolution (ADR) proceedings against AstraZeneca over its conditions on 340B contract pharmacy yesterday asked the panel hearing its claim to deny the drug company’s motion to stay the proceedings.

Little

Read More »

Three Drug Makers, Including Two with Contract Pharmacy Restrictions, Post 340B Refund Notices

Bristol Myers Squibb, Novo Nordisk, and Ipsen Biopharmaceuticals notified 340B covered entities this week about refunds for charges above 340B ceiling prices.

Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.

Bristol Myers Squibb (BMS) and Novo Nordisk’s notices came to light yesterday

Read More »

With Public Health Emergency Extended, 340B Flexibilities to Continue

340B program flexibilities will continue for another 90 days under the latest extension of the COVID-19 national public health emergency.

340B program flexibilities will continue under the eighth 90-day extension of the COVID-19 national public health emergency (PHE) late last week.

U.S. Health and Human Services (HHS) Secretary Xavier Becerra renewed the PHE on Friday, Jan. 14.

In

Read More »

In Big Win for Pharmacy Groups, CMS Proposes Significant Changes to Medicare Part D Clawbacks

CMS wants to change Medicare Part D rules to rein in PBMs' controversial practice of clawing back drug payments to pharmacies after point of sale.

The Centers for Medicare & Medicaid Services (CMS) yesterday proposed changing Medicare Part D rules to curb plan sponsors and pharmacy benefit managers’ skyrocketing use of direct and indirect renumeration fees (DIR)—PBMs’ controversial practice of clawing back drug payments to

Read More »

Judge Denies Calif. 340B Health Centers’ Motion to Halt State Medicaid Drug Payment Change

California health centers say they will continue to fight against the transfer of state Medicaid managed care drug coverage to Medicaid fee for service, despite being denied a temporary restraining order against the change.

A federal judge in Sacramento, Calif., late yesterday declined to stop California Medicaid’s transfer of managed care drug coverage to Medicaid fee for service that took effect on Jan. 1. Health centers enrolled in the 340B drug pricing program pledged

Read More »

Carole Johnson Takes Charge of HRSA and the 340B Program

Carole Johnson's tenure as HRSA administrator officially began this week Tuesday.

The U.S. Health Resources and Services Administration (HRSA), the agency that runs the 340B drug pricing program, has a permanent leader again for the first time in almost a year.

Carole Johnson started in her position as HRSA administrator on

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report